Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy by Matsuura, Hiroko et al.
Chemistry
Biochemistry fields
Okayama University Year 2008
Association of elevated plasma B-type
natriuretic peptide levels with
paroxysmal atrial fibrillation in patients
with nonobstructive hypertrophic
cardiomyopathy
Hiroko Matsuura, Department of Medicine and Medical Science,
Okayama University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences
Takashi Murakami, Department of Cardiology, Cardiovascular Cen-
ter, Sakakibara Hospital
Kazuyoshi Hina, Department of Cardiology, Cardiovascular Center,
Sakakibara Hospital
Keizo Yamamoto, Department of Cardiology, Cardiovascular Cen-
ter, Sakakibara Hospital
Hiroshi Kawamura, Department of Cardiology, Cardiovascular Cen-
ter, Sakakibara Hospital
Taiji Sogo, Department of Cardiovascular Medicine, Takamatsu Red
Cross Hospital
Ryoko Shinohata, Department of Medical Technology, Okayama Uni-
versity Graduate School of Health Sciences
Shinichi Usui, Department of Medical Technology, Okayama Univer-
sity Graduate School of Health Sciences
Yoshifumi Ninomiya, Department of Molecular Biology and Bio-
chemistry, Okayama University Graduate School of Medicine, Den-
tistry and Pharmaceutical Sciences
Shozo Kusachi, Department of Medical Technology, Okayama Uni-
versity Graduate School of Health Sciences
This paper is posted at eScholarship@OUDIR : Okayama University Digital Information
Repository.
http://escholarship.lib.okayama-u.ac.jp/biochemistry/12
BNP, HCM and Atrial Fibrillation 
Association of elevated plasma B-type natriuretic peptide levels with paroxysmal 
atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy 
 
Hiroko Matsuura, MD,  Takashi Murakami, MD†,  Kazuyoshi Hina, MD†, 
Keizo Yamamoto, MD†,  Hiroshi Kawamura, MD†,  Taiji Sogo, MD‡,   
Ryoko Shinohata, MT**,  Shinichi Usui, MT**,  Yoshifumi Ninomiya, MD*, 
Shozo Kusachi, MD** 
 
Department of Medicine and Medical Science and *Department of Molecular Biology 
and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, and **Department of Medical Technology, Okayama 
University Graduate School of Health Sciences, Okayama, and †Department of 
Cardiology, Cardiovascular Center, Sakakibara Hospital, Okayama, Department of 
Cardiovascular Medicine, ‡Takamatsu Red Cross Hospital, Takamatsu, Japan  
Running title: BNP, HCM and Atrial Fibrillation 
Category: Clinical Investigation, Full paper 
Address correspondence to: 
Shozo Kusachi, MD 
Department of Medical Technology 
Okayama University Graduate School of Health Sciences, 
2-5-1, Shikata-cho, Okayama 700-8558, Japan.  
(Ph. Japan +81-86-235-6897, Fax Japan +81-86-235-6897, +81-86-222-7768)  
(E-mail: sh-ksc56@po1.oninet.ne.jp )(secondary address: ykz93ssk@po1.oninet.ne.jp) 
 1
BNP, HCM and Atrial Fibrillation 
Abstract   
Objectives: To investigate the relationship between the plasma B-type natriuretic 
peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive 
hypertrophic cardiomyopathy (HCM) patients.   
Methods: Patients (n=97) were classified into chronic AF (CAF; n=14), paroxysmal 
AF (PAF; n=18) and normal sinus rhythm (NSR; n=65) groups.  The plasma BNP 
values were analyzed with logarithmic transformation. 
Results: The PAF group showed significantly higher plasma BNP levels than the NSR 
group [mean (range; -lSD and +1SD); 248.3 (143.5, 429.5) vs 78.2 (27.9, 218.8 ng/L), 
p<0.0001].  The CAF group also showed significantly higher plasma BNP levels than 
the NSR group [291.1 (161.4, 524.8 ng/L), p<0.0001].  Multivariate analysis with 
other clinical factors selected association of PAF as one of the factors that increased 
the plasma BNP level. 
Conclusions: The present study indicated that plasma BNP level is clinically useful 
for identification of nonobstructive HCM patients who have a risk of PAF. 
 
Keywords:  clinical study, cardiomyopathy, tachyarrhythmia, enzyme immunoassay, 
peptide, sensitivity and specificity 
 2
BNP, HCM and Atrial Fibrillation 
Introduction 
 
B-type natriuretic peptide (BNP) is a peptide hormone derived from atrial and 
ventricular cardiomyocytes [1-3].  Circulating plasma BNP levels have been well 
documented to be elevated in conditions characterized by various cardiac overloads 
[3-7].  BNP activation reflects hemodynamic alterations and left ventricular 
dysfunction.  The plasma BNP level thus provides prognostic information and is an 
important clinical tool [1, 8-10].  Atrial fibrillation (AF) causes ventricular 
hemodynamic alterations as well as atrial overload, and the plasma BNP level has also 
been reported to be increased in patients with AF [11], even after controlling for 
demographic and clinical variables [12].  Conversely, cardioversion from AF to sinus 
rhythm decreased the plasma BNP level [13-15]. 
AF is a common complication of hypertrophic cardiomyopathy (HCM), with an 
incidence ranging between 10 and 40% [16-19].  AF causes deterioration in 
hemodynamic conditions, progression of heart failure and increased risk of 
thromboembolism in HCM [20, 21].  Treatment of association of paroxysmal AF 
(PAF) usually requires anticoagulant and/or antithrombotic therapy.  The opportunity 
for detection of PAF is thought to be low in nonobstructive HCM patients compared 
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with obstructive HCM patients or HCM patients with heart failure, since the latter two 
types of patients require extensive treatment and frequent examination.  From these 
considerations, even in nonobstructive HCM patients in the early phase of HCM, 
detection of PAF at an early time is quite important with respect to choosing a 
treatment strategy.  
 Based on these reported findings, we hypothesized that the plasma BNP level 
would be elevated in HCM patients, including nonobstructive HCM patients, with PAF 
compared to those with normal sinus rhythm (NSR).  There are, however, no studies 
that measured plasma BNP levels in nonobstructive HCM patients in connection with 
AF.  Accordingly, we determined plasma BNP levels in nonobstructive HCM patients 
and compared the values among nonobstructive HCM patients with NSR, those with 
PAF and those with chronic AF (CAF). 
 
Patients and methods 
Enrollment of outpatients with nonobstructive HCM in the present study was carried 
out from July, 2001 to December, 2005 at Sakakibara Hospital (Okayama, Japan) and 
Takamatsu Red Cross Hospital (Takamatsu, Japan).  Patients with pathological 
conditions other than arrhythmia status associated with HCM that cause an increase in 
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plasma BNP level were excluded from the study.  The underlying pathological 
conditions for the exclusion were disturbed renal function (serum creatinine greater 
than our institutional normal range: 100 μmol/L), lung disease, hypertension and other 
organic heart disease such as valvular heart disease.  From a clinical standpoint, 
classification of HCM based on hemodynamic overload is important.  Patients with 
subaortic, outflow tract and midventricular obstruction at rest or on provocation were 
excluded from the present study.  Patients with decreased left ventricular systolic 
function [left ventricular ejection fraction (LVEF) < 50%] or with heart failure [New 
York Heart Association (NYHA) functional class ≥ III] were also excluded from the 
present analysis.  During enrollment of patients in the present study, among a total of 
122 HCM outpatients, 21, 2 and 2 patients had outflow tract obstruction, heart failure 
with NYHA functional class ≥ III and LVEF < 50%, respectively.  The present study 
finally included 97 outpatients with nonobstructive HCM without significantly 
reduced ventricular performance.  The patients’ clinical characteristics are listed in 
Table 1.  The study was in compliance with the rules of the Helsinki Declaration, 
informed consent was obtained from all these patients, and the study was approved by 
institutional ethics committee for human research [22]. 
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We determined plasma BNP levels during NSR within 3 months (mean±SD, 
1.7±0.8, range 1 to 3 months) after an AF episode in 18 patients with PAF.  AF was 
demonstrated by 12-lead ECG when patients visited our hospital with symptoms of 
palpitation, dyspnea and/or chest discomfort.  PAF was diagnosed based on 
guidelines for the management of AF [23].  Plasma BNP was measured at the time of 
enrollment in 14 patients with CAF, which was defined as ECG documentation of AF 
at the time of plasma BNP measurements and electrocardiographic AF documentation 
in every visit to our outpatient clinic [23].  In addition, plasma BNP levels were 
determined at the time of enrollment in 65 nonobstructive HCM patients with NSR, 
which was defined as NSR in 12-lead ECG recorded at every visit for outpatients or in 
Holter ECG examination, and the absence of any symptoms that suggested transient 
AF attacks.  We followed-up these patients until February 2007 and the follow-up 
periods were > 1 year (4.39±2.00 years; 1.1 - 6.8 years) after the initial measurement 
of plasma BNP level.  We followed these patients basically once every 4 - 8 weeks at 
our out-patient clinic.  During the follow-up period, we examined the 12-lead ECG 
and carefully checked symptoms that suggested transient AF attacks.  Holter ECG 
was not recorded at scheduled intervals and was performed only when needed.  No 
patients with PAF or NSR progressed to recurrent persistent AF or permanent AF, at 
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least within 1 year after the plasma BNP measurements.  Patients with NSR and CAF 
showed stable conditions for at least 1 year after the plasma BNP measurements.  
 
Blood sampling 
As stated above, blood sampling was performed during NSR within 3 months after an 
AF episode in PAF patients and the time of enrollment in CAF and NSR patients.  
Blood was drawn from a peripheral vein into ethylenediaminetetraacetic 
acid-containing tubes and plasma was immediately separated.  Plasma BNP levels in 
all samples were subsequently determined immediately using a sandwich 
fluoroenzyme immunoassay method with automatic immunoassay equipment (AIA 
600II, TOSOH, Tokyo, Japan) with a reagent kit [E test, TOSOH II (BNP)] at the 
central laboratory of each hospital (Sakakibara Hospital and Takamatsu Red Cross 
Hospital) by medical technologists who were experienced experts in bioassays and not 
aware of the any clinical information about the patients.  The measurements were 
thus completed within less than 30 minutes.  This assay system uses two monoclonal 
antibodies against human BNP: one recognizing the carboxy-terminal sequence (amino 
acids 27-32) and the other the ring structure of human BNP (amino acids 14-21), and 
does not cross react with atrial or C type natriuretic peptide [24, 25].   Both antibodies 
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were supplied by Shionogi & Co., Ltd. (Osaka, Japan) and have been widely used to 
demonstrate the clinical usefulness of BNP measurements.  BNP measurements were 
performed according to manufacturer’s instruction manual and calibration was 
performed by a 6-point calibration using BNP samples with known concentrations 
with appropriate timing, as indicated by the instruction manual.  The upper reference 
value is 18.4 ng/L, with a detection limit of 1.9 ng/L.  The intra-assay coefficient of 
variation in the automated assay system was 2.1%, 1.9% and 1.1% at 32.5, 185.3 and 
715.0 ng/L, respectively.  The coefficient of variation for between-run reproducibility 
was 1.3%, 1.2% and 1.7% at 30.0, 180.0 and 696.4 ng/L, respectively. 
 
Echocardiographic Measurements 
Transthoracic M-mode, two-dimensional and Doppler echocardiography were 
performed using Toshiba SSA390A equipment (Toshiba Medical Systems, Tokyo, 
Japan) on the day of plasma BNP measurements or within 2 weeks after plasma BNP 
measurements.  All examinations were performed by 2 medical technologists who 
were experienced experts in echocardiographic measurements and not aware of the 
clinical background of the patients.  Echocardiographic recordings were performed in 
the long-axis parasternal plane and in the apical four- and two-chamber plane. 
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Measurements were made according to the guidelines laid down by the American 
Society of Echocardiography [26].  The left atrial dimension (LAD) and left 
ventricular end-diastolic (LVEdD) and end-systolic dimension (LVEsD) were assessed 
by M-mode echocardiography in a standard fashion.  LV hypertrophy was determined 
with two-dimensional echocardiographic recordings according to established criteria 
[27].  The greatest thickness measured at any site in the LV wall was considered to 
represent maximal LV wall thickness [16].  Peak instantaneous LV outflow gradient 
was estimated under basal conditions with continuous-wave Doppler [28].  Diagnosis 
of HCM was based on echocardiographic features of a hypertrophied, non-dilated LV 




Because the distribution pattern of plasma BNP values did not appear to be normal, 
and the values were considerably shifted to one side, the values were transformed into 
a common logarithm (LogBNP) [30].  Data are expressed as mean±SD range.  The 
t-test or Mann-Whitney U test was used to compare data between the 2 groups when 
appropriate.  We employed one-way analysis of variance (ANOVA) for comparison 
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of 3 groups’ data.  Bonferroni’s post-hoc t-test was also used to assess the differences 
of data between any 2 of the CAF, PAF and NSR groups.  Area under the curve 
(AUC) and optimum cutoff level of each factor were determined by analyses of 
receiver operating characteristic curves (ROC curves).  In ROC curves, when various 
cutoff values were selected, the relationship between the values of (sensitivity) and 
(1-specificity) were plotted. The optimum cutoff was determined as the value that 
maximized the likelihood ratio (LR) obtained using the formula: LR = (sensitivity)/(1 
-specificity) [31].  In other words, diagrammatically, the optimum cutoff can be 
chosen as the value that minimizes the distance from the upper left corner of the plot 
frame.  The 95% confidence intervals for sensitivity and specificity were obtained 
using an appropriate program for a small number of cases that employs the 
relationship between inverse F-distribution, inverse beta function and binomial to get 
the "exact" binomial confidence interval [32, 33].  In patients with PAF and NSR, 
stepwise linear regression analysis was also performed with BNP as the dependent 
variable.  Independent variables enrolled were association with PAF, age, gender, 
echocardiographic indices (LAD, LVEdD, LVEsD), drugs used, and association with 
diabetes mellitus.  A p value of < 0.05 was considered significant. 
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Results 
Plasma BNP levels 
The PAF group showed significantly higher plasma BNP levels than the NSR group 
[plasma LogBNP level: 2.395±0.238 vs 1.893±0.447; plasma BNP level: mean (range 
–l SD and +1SD): 248.3 (143.5, 429.5) vs 78.2 (27.9, 218.8 ng/L) p<0.0001] (Fig. 1).  
There was not a large overlap of plasma LogBNP level between the PAF and NSR 
groups.  The CAF group also showed significantly higher plasma BNP levels than the 
NSR group [plasma LogBNP levels: 2.464±0.256; plasma BNP levels: 291.1 (161.4, 
524.8 ng/L) p<0.0001].  There were, however, no significant differences in plasma 
BNP levels between the PAF and CAF groups.  
ROC curve analysis was performed to obtain cutoff values of the plasma BNP 
level for distinguishing the PAF group from the NSR group (Fig. 2).  The area under 
the ROC curve (AUC) was 0.84 [standard error (SE) 0.05; 95% confidence interval 
(CI), 0.75 - 0.92; p<0.001), which indicted that plasma BNP level was useful for 
distinguishing HCM patients with PAF from those with NSR.  The 
specificity-sensitivity curve indicated that 72.3% specificity (95% CI, 59.8 - 82.7%) 
and 83.3% sensitivity (95% CI, 58.6 - 96.4%) were obtained with a cut-off value of 
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151.4 ng/L (plasma LogBNP level; 2.18) for distinguishing the PAF group from the 
NSR group. 
 
Relationship of plasma BNP level with echocardiographic indices 
Plasma LogBNP level was significantly correlated with LAD (r=0.47, p<0.0001). 
There were, however, no significant differences in LAD between the PAF group 
(43.4±10.4 mm) and the NSR group (39.9±4.9 mm), and therefore no significant AUC 
was obtained in the ROC analysis.  There was no significant correlation between 
plasma LogBNP level and LVEdD or LVEsD, and no significant differences in either 
of these dimensions between the PAF and NSR groups. 
 
Drugs 
There were no significant differences in plasma LogBNP levels between patients with 




The results of stepwise multiple linear regression analysis are shown in Table 2.  The 
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stepwise analysis selected association of PAF as one of the factors that increased 




The present study revealed that patients with PAF showed significantly higher 
plasma BNP levels than patients with NSR.  ROC curve analysis revealed that plasma 
BNP level was clinically useful to identify HCM patients at risk for PAF. 
 The present results showed that plasma BNP levels were elevated even in 
nonobstructive HCM patients with NSR.  Similar plasma BNP levels have been 
reported in nonobstructive HCM with NSR [34].  Another study observed similar 
plasma BNP levels in HCM patients of NYHA functional class I [35].  These reported 
results were in good agreement with the present results.  Markedly elevated plasma 
BNP levels have been demonstrated in obstructive HCM and HCM with heart failure 
compared to uncomplicated nonobstructive HCM [34, 35].  These lines of evidence 
indicate that to examine the effects of AF on plasma BNP levels in HCM patients, it is 
essential to consider underlying pathological hemodynamic overload conditions.  The 
present study therefore excluded HCM patients with LV obstructive condition, heart 
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failure or decreased LVEF and focused on identification of nonobstructive HCM 
patients with PAF.  The fact that the basal data were identical with reported results 
indicated that the present analytical methods were valid. 
   The present results demonstrated that plasma BNP level was associated with AF.  
Increased plasma BNP level in patients with lone AF has recently been demonstrated 
[36].  Moreover, PAF patients without any structural heart disease have also been 
shown to exhibit increases in plasma BNP levels [37].  Our finding that plasma BNP 
levels were elevated, with mean values in decreasing order for CAF, PAF and NSR, 
were completely in agreement with these recently reported results.   
   The present study indicated that plasma BNP level may provide considerable 
information for distinguishing the PAF group from the NSR group.  Although the 
present study did not find significant differences in LAD between nonobstructive 
HCM patients with PAF and those with NSR, there are reports of the detection of PAF 
patients with HCM using other markers such us echocardiographic measurements and 
12-lead electrocardiographic findings [38-40].  LAD dimension, LA volume 
determined with area length methods and p wave duration obtained by signal-averaged 
electrocardiogram have also been used to attempt to detect association of PAF in HCM 
patients, and have been reported to possess similar distinguishing powers to those of 
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plasma BNP level.  These measurements impose certain inconveniences on patients.  
Furthermore, these measurements require skillful and stable techniques, time-cost 
and/or special equipment for determination.  In contrast, blood sampling itself for 
plasma BNP measurements does not have these disadvantages.  Although plasma 
BNP measurements require precise standardization, plasma BNP level measured 
carefully using the automated equipment employed in the present study is clinically 
useful to identify HCM patients who have a risk for development of CAF. 
There were no significant differences in LVEdD or LVEsD between patients with 
PAF and those without.  In addition, plasma LogBNP level was not significantly 
correlated with these indices.  Only HCM patients with preserved LV function and 
without outflow pressure gradient were enrolled in the present study.  This strict 
patient selection may account for the lack of a significant difference in plasma 
LogBNP levels between the groups, and for the dissociation of plasma LogBNP levels 
and these LV indices.  The present results comparing plasma BNP levels and 
echocardiographic indices among the 3 groups of HCM patients suggested that plasma 
BNP level was more sensitive than echocardiographic indices for detecting cardiac 
overloading caused by AF.  
There were several limitations in the present study.  First, it included a relatively 
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small number of patients due to the careful patient selection.  Our careful patient 
selection based on theoretical criteria may have compensated for this limitation, and 
the fact that our results were consistent with those of reports that examined only HCM 
patients and patients with lone AF support this idea.  Furthermore, significant and 
clinically useful differences between HCM patients with PAF and those with NSR 
were demonstrated by careful statistical analyses.  This limitation was thus not a 
major weakness of the present study.  Second, the relationship of the extent of PAF, 
that is, the frequency and duration of PAF, and plasma BNP level could not be 
clarified.  Precise documentation of the frequency and duration of PAF was generally 
impossible.  The present results, however, showed that plasma BNP level would at 
least be useful for identifying HCM patients with symptomatic PAF that occurred 
recently. 
   In conclusion, the present study indicated that plasma BNP level is clinically useful 
for the identification of HCM patients who have a risk of PAF. 
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Box-plot representation of the common log transformed plasma BNP levels 
(LogBNP) distribution among HCM patients with normal sinus rhythm (NSR), those 
with paroxysmal atrial fibrillation (PAF) and those with chronic atrial fibrillation 
(CAF).  Lines within boxes represent medians.  The lower and upper boundaries of 
the boxes mark the 25th and 75th percentiles, and the bars below and above the boxes 
indicate the 10th and 90th percentiles.  P, probability value. 
 
Figure 2. 
Receiver operating characteristic curves of logarithmic transformed plasma BNP level 
(LogBNP) for distinguishing paroxysmal AF (PAF) group from normal sinus rhythm 
(NSR) group.  AUC, area under the curve. 
 
 
BNP, HCM and Atrial Fibrillation 
Table 1. Patients' Characteristics    
  NSR PAF CAF p 
Cases 65 18 14  
Age (years) 62.3 ± 12.1 62.4 ± 10.1 72.7 ± 7.4 <0.01  
Gender (M:F) 42 : 23 14 : 4 10 : 4 ns  
SBP (mmHg) 119.7 ± 10.1 120.1 ± 10.7 115.9 ± 12.6 ns  
DBP (mmHg) 70.1 ± 9.0 71.4 ± 7.3 66.9 ± 8.4 ns  
Diabetes mellitus (%) 5 (7.7) 3 (16.7) 3 (21.4)  ns 
Drugs      
β blocker (%) 41 (63.1) 10 (55.6) 2 (14.3) <0.005  
ARB or ACEI (%) 26 (40.0)   6 (33.3) 8 (57.1) ns  
Verapamil (%)  6 ( 9.2)   3 (16.7) 5 (35.7) <0.05 
Diuretics (%) 0 0 0 / 
M, male; F, female; NSR, normal sinus rhythm; PAF, paroxysmal atrial fibrillation; CAF, 























BNP association of PAF 159.22  32.90  0.4477  0.4829  0.00001
 LAD 6.31  2.23  0.2621  0.3067  0.00597
 β blocker 60.93  27.29  0.2023  0.2466  0.02847
 diabetes mellitus -95.05  45.96  -0.1914 -0.2294 0.04199
 age 2.05  1.16  0.1612  0.1981  0.08012
    multiple regression coefficient r=0.623, p<0.0001 
BNP, B-type natriuretic peptide; PAF, paroxysmal atrial fibrillation; p, probability value.  Use of values for each selected factor was as 
follows: association of PAF as 1, NSR as 0; LAD, actual values; β blocker, administered as 1, non-administered as 0; diabetes mellitus, 
association with diabetes mellitus as 1, without as 0; age, actual values. 
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